You are viewing the site in preview mode
Skip to main content
| |
Univariate Hazard Model
|
|
Recurrence-Free Survival
|
Overall Survival
|
|
HR
|
95% CI
|
P-value
|
HR
|
95% CI
|
P-value
|
|
NY-ESO-1 Vaccine
|
0.555
|
(0.374, 0.822)
|
0.0034
|
0.507
|
(0.310, 0.831)
|
0.007
|
|
Thickness (1 mm)
|
1.079
|
(1.044, 1.116)
|
< 0.0001
|
1.101
|
(1.062, 1.141)
|
< 0.0001
|
|
Ulceration
|
Absent
|
1
| | |
1
| | |
|
Present
|
2.206
|
(1.490, 3.266)
|
< 0.0001
|
2.185
|
(1.336, 3.573)
|
0.0019
|
|
Undetermined
|
1.079
|
(0.600, 1.940)
|
0.8002
|
0.953
|
(0.413, 2.196)
|
0.9093
|
|
Age (1 year)
|
1.015
|
(1.002, 1.027)
|
0.0201
|
1.025
|
(1.008, 1.042)
|
0.0033
|
|
AJCC Stage
|
IIIA
|
1
| | |
1
| | |
|
IIIB
|
1.141
|
(0.730, 1.783)
|
0.5627
|
1.005
|
(0.643, 1.570)
|
0.9842
|
|
IIIC
|
1.795
|
(1.130, 2.850)
|
0.0132
|
1.457
|
(0.915, 2.319)
|
0.1129
|
| |
Multivariate Hazard Model
|
|
Recurrence-Free Survival
|
Overall Survival
|
|
HR
|
95% CI
|
P-value
|
HR
|
95% CI
|
P-value
|
|
NY-ESO-1 Vaccine
|
0.454
|
(0.301, 0.685)
|
0.0002
|
0.403
|
(0.269, 0.604)
|
< 0.0001
|
|
AJCC Stage
|
IIIA
|
1
|
(0.561, 1.370)
| |
1
| | |
|
IIIB
|
1.225
|
(0.783, 1.916)
|
0.3744
|
1.028
|
(0.658, 1.608)
|
0.9026
|
|
IIIC
|
2.348
|
(1.452, 3.797)
|
0.0005
|
1.792
|
(1.114, 2.883)
|
0.0161
|
